Make sure to stay updated. HAEi will keep you informed when you sign up for our newsletter.
Sign up for HAEi Newsletter and register at the same time.
1020 First Avenue
P O Box 61501
King of Prussia, PA 19406
United States of America
CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies that are used to treat serious and rare conditions. Users of our therapies rely on them for their quality of life and, in many cases, for life itself. Our commitment to saving lives and improving the quality of life for people with serious and rare conditions is evident in everything we do.
CSL Behring (Berinert brand of C1 inhibitor) has completed its phase 3 trial of Berinert-P, a C1 inhibitor concentrate product that is produced from US source plasma at the company's plant in Marburg, Germany, and sold throughout the world. Berinert has an impressive long term safety record and, in countries where available, is the drug of choice for acute HAE attacks.
Approved by EMEA for treatment of attacks in all 27 EU countries
Approved by FDA for treatment of acute attacks in the United States of America